Fig 5 - by Jacob C. Jentzer (4746999)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Ageing results in an abrupt decrease in overall neurogenesis in the mouse DG. by Joana Gil-Mohapel (462002)

“…(C) An estimation of overall neurogenesis based on the total number of BrdU-positive cells that survived the 42-day period multiplied by the proportion of BrdU-positive cells that acquired a mature neuronal phenotype indicates an age-induced significant and abrupt decrease in the overall number of new neurons. *** <i>p</i> < 0.001 between 1.5 and 3 months and between 3 and 6 months. …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Decrease of full-length tRNAs under oxidative stress. by Jiayong Zhong (757895)

“…The data are shown as the mean ± SD. (C) Decreased tRNA levels following 30 min of OS, measured by next-generation sequencing. …”

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antidepressants decrease β-catenin-induced liver enlargement and tumorigenesis. by Kimberley J. Evason (764570)

Overexpressions of the AB domain of RPA70 and the β-barrel domain of Ku70 significantly decrease HBoV1 replication in HAE-ALI. by Kang Ning (59789)

“…Duplex HBoV1 genome was loaded as a size marker (M) of 5.5 kb. …”